Patient guide · Reviewed June 2026
PBS or Private Now? A Decision Guide for Wegovy and Mounjaro in 2026
If you're considering starting Wegovy or Mounjaro and wondering whether to pay privately now or wait for possible PBS subsidisation, here's the current state of play in 2026 — because the two medications are in very different positions.
Published 2026-06-01 · Clinically reviewed 2026-06-03
Patient guide · Reviewed June 2026
Wegovy: PBS listing is coming, but the eligibility is narrow
In late 2025, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended Wegovy (semaglutide 2.4 mg) for PBS listing, and this progressed to formal…
In late 2025, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended Wegovy (semaglutide 2.4 mg) for PBS listing, and this progressed to formal government planning in January 2026. But before you wait on the assumption you'll qualify, look closely at who the recommendation actually covers.
The PBAC recommendation is explicitly not for general weight loss. It is restricted to secondary prevention in patients with established cardiovascular disease. To meet the recommended criteria, a patient must have:
- A BMI of 27 kg/m² or above, and
- Established cardiovascular disease — defined as a prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease
Because of the high fiscal cost of subsidising obesity treatment broadly, the PBAC restricted the recommendation to this defined cardiovascular cohort. The committee raised explicit concern about "leakage" — off-label use beyond the approved group — and noted that broader, earlier-intervention weight-management access would likely need to be managed through a separate public health program outside the PBS altogether, because subsidising the full eligible population within the current PBS framework isn't considered cost-effective.
What this means practically: if you have established cardiovascular disease and a BMI ≥27, and you meet the specific PBAC criteria once finalised, waiting could mean paying as little as $31.60 per month (or $7.70 with a concession card) instead of $250–$450 privately. If you don't meet that narrower cardiovascular criteria — which describes most people seeking GLP-1 therapy purely for weight management without a prior cardiovascular event — the PBS listing won't apply to you, and waiting achieves nothing.
The timing is also still genuinely uncertain. As of early 2026, the exact listing date and final pricing remain under negotiation between Novo Nordisk and the federal government — meaning even eligible patients may be waiting several more months before subsidised access actually becomes available.
Mounjaro: don't wait — there's currently no near-term PBS pathway
Mounjaro's situation is materially different, and more clear-cut. In April 2026, Eli Lilly officially rejected a PBAC recommendation to list Mounjaro on the PBS for type 2 diabetes, describing the government's proposed pricing as "unrealistic and unviable" relative to prices negotiated in other countries. Eli Lilly's leadership has indicated this diabetes-listing breakdown will also impede future submissions for other indications — meaning a PBS listing for Mounjaro for obesity is considered highly unlikely in the near term.
If you're weighing up whether to wait for subsidised Mounjaro, the honest, current answer is: there's no indication that's coming soon. Mounjaro remains a private-market medication only, at approximately $285–$699 per month depending on your maintenance dose.
Patient guide · Reviewed June 2026
So which decision is right for you?
| Your situation | What the current evidence suggests |
|---|---|
| You have established cardiovascular disease (prior MI, stroke, or symptomatic PAD) and a BMI ≥27 | Worth discussing with your GP whether waiting for the Wegovy PBS listing makes sense for you specifically — but confirm eligibility against the exact criteria rather than assuming it |
| You want GLP-1 therapy primarily for weight management, without a prior cardiovascular event | The PBS listing is unlikely to apply to you; the decision is really "start privately now" vs "don't start," not "wait or pay" |
| You're specifically interested in Mounjaro/tirzepatide | There's currently no near-term subsidised pathway in sight; the realistic choice is private-pay now or a different medication |
| Cost is the primary barrier either way | It's worth discussing the full annualised cost (medication, monitoring, scans) with your GP before committing either way — the true cost is higher than the medication price alone |
The honest bottom line
PBS listings move slower and narrower than most people assume — the Wegovy recommendation looks like genuine progress, but it's targeted at a specific high-risk cardiovascular group, not a general greenlight for subsidised weight-loss access. If you're not confident you'd meet the eventual criteria, the practical decision usually comes down to whether starting now, privately, makes sense for your individual health situation — a conversation worth having directly with your GP rather than basing the decision on headlines about the PBAC recommendation alone.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Will Wegovy be on the PBS for weight loss in Australia?
The PBAC recommendation is for secondary cardiovascular prevention in patients with BMI ≥27 and established cardiovascular disease — not general weight management.
Should I wait for PBS Wegovy or pay privately?
Only if you meet the narrow cardiovascular criteria. Most people seeking GLP-1 for weight management without prior cardiovascular events won't qualify.
Is Mounjaro on the PBS in Australia?
No near-term pathway. Eli Lilly rejected the April 2026 PBAC diabetes listing recommendation, making obesity PBS access unlikely soon.
How much does private Wegovy cost in Australia?
Approximately $259–$389 per month depending on dose. See our true cost guide for the full annual picture including monitoring.
Pharmaceutical Benefits Advisory Committee, Wegovy PBS recommendation, late 2025/January 2026 planning; reporting on Eli Lilly's April 2026 rejection of the Mounjaro PBAC pricing recommendation for type 2 diabetes.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.